Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.41 |
| ▸ | STAT5B | P51692 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1178979 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL48809 | 0.79 | — | — | |
| Acetic Acid SCHEMBL10839556 | 0.78 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL20942702 | 0.75 | TP53 (0.55) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL21111119 | 0.75 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL6373759 | 0.74 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL3643462 | 0.73 | — | — | |
| SCHEMBL10633950 | 0.73 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL2360784 | 0.72 | FOLH1 (0.39) | ALDH1A1 | |
| SCHEMBL10636720 | 0.72 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | ALDH1A1 394/4885MEN1 2143/4885KMT2A 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.